The BBXB Motif of RANTES Is the Principal Site for Heparin Binding and Controls Receptor Selectivity

The chemokine RANTES (regulated on activation normal T cell expressed and secreted; CCL5) binds selectively to glycosaminoglycans (GAGs) such as heparin, chondroitin sulfate, and dermatan sulfate. The primary sequence of RANTES contains two clusters of basic residues, 44RKNR47 and55KKWVR59. The firs...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Journal of biological chemistry 2001-04, Vol.276 (14), p.10620-10626
Hauptverfasser: Proudfoot, Amanda E.I., Fritchley, Sarah, Borlat, Frédéric, Shaw, Jeffrey P., Vilbois, Francis, Zwahlen, Catherine, Trkola, Alexandra, Marchant, David, Clapham, Paul R., Wells, Timothy N.C.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 10626
container_issue 14
container_start_page 10620
container_title The Journal of biological chemistry
container_volume 276
creator Proudfoot, Amanda E.I.
Fritchley, Sarah
Borlat, Frédéric
Shaw, Jeffrey P.
Vilbois, Francis
Zwahlen, Catherine
Trkola, Alexandra
Marchant, David
Clapham, Paul R.
Wells, Timothy N.C.
description The chemokine RANTES (regulated on activation normal T cell expressed and secreted; CCL5) binds selectively to glycosaminoglycans (GAGs) such as heparin, chondroitin sulfate, and dermatan sulfate. The primary sequence of RANTES contains two clusters of basic residues, 44RKNR47 and55KKWVR59. The first is a BBXB motif common in heparin-binding proteins, and the second is located in the loop directly preceding the C-terminal helix. We have mutated these residues to alanine, both as point mutations as well as triple mutations of the 40s and 50s clusters. Using a binding assay to heparin beads with radiolabeled proteins, the44AANA47 mutant demonstrated an 80% reduction in its capacity to bind heparin, whereas the55AAWVA59 mutant retained full binding capacity. Mutation of the 44RKNR47 site reduced the selectivity of RANTES binding to different GAGs. The mutants were tested for their integrity by receptor binding assays on CCR1 and CCR5 as well as their ability to induce chemotaxis in vitro. In all assays the single point mutations and the triple 50s cluster mutation caused no significant difference in activity compared with the wild type sequence. However, the triple 40s mutant showed a 80-fold reduction in affinity for CCR1, despite normal binding to CCR5. It was only able to induce monocyte chemotaxis at micromolar concentrations. The triple 40s mutant was also able to inhibit HIV-1 infectivity, but consistent with its abrogated GAG binding capacity, it no longer induced enhanced infectivity at high concentrations.
doi_str_mv 10.1074/jbc.M010867200
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_77012028</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0021925819344904</els_id><sourcerecordid>77012028</sourcerecordid><originalsourceid>FETCH-LOGICAL-c475t-a6cdd54825bf301cdd4a6d4970127049a56af056c11d84300ec9e0b2ff79d9ab3</originalsourceid><addsrcrecordid>eNp1kE1PGzEQhq2KqqTAtcfKB8Rt07H3-0iiUJCgRSRI3CyvPSZGm_ViOyD-fR0lEqfOxR77mVejh5AfDKYM6uLXS6emd8CgqWoO8IVM0jXP8pI9HZEJAGdZy8vmmHwP4QVSFS37Ro5ZqoqVzYTo1RrpbPY0o3cuWkOdoQ-Xf1aLJb0JNKa_e28HZUfZ06WNSI3z9BpHmV7pzA7aDs9UDprO3RC96wN9QIVjTNQSe1TRvtn4cUq-GtkHPDucJ-TxarGaX2e3f3_fzC9vM1XUZcxkpbQui4aXncmBpaaQlS7aGhiv0-ayrKSBslKM6abIAVC1CB03pm51K7v8hFzsc0fvXrcYotjYoLDv5YBuG0S9SwLeJHC6B5V3IXg0YvR2I_2HYCB2XkXyKj69poGfh-Rtt0H9iR9EJuB8D6zt8_rdehSddWqNG8HrSrAipVZ8l9PsMUwa3ix6EZTFQaFOIyoK7ez_VvgHUbWQuw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>77012028</pqid></control><display><type>article</type><title>The BBXB Motif of RANTES Is the Principal Site for Heparin Binding and Controls Receptor Selectivity</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Proudfoot, Amanda E.I. ; Fritchley, Sarah ; Borlat, Frédéric ; Shaw, Jeffrey P. ; Vilbois, Francis ; Zwahlen, Catherine ; Trkola, Alexandra ; Marchant, David ; Clapham, Paul R. ; Wells, Timothy N.C.</creator><creatorcontrib>Proudfoot, Amanda E.I. ; Fritchley, Sarah ; Borlat, Frédéric ; Shaw, Jeffrey P. ; Vilbois, Francis ; Zwahlen, Catherine ; Trkola, Alexandra ; Marchant, David ; Clapham, Paul R. ; Wells, Timothy N.C.</creatorcontrib><description>The chemokine RANTES (regulated on activation normal T cell expressed and secreted; CCL5) binds selectively to glycosaminoglycans (GAGs) such as heparin, chondroitin sulfate, and dermatan sulfate. The primary sequence of RANTES contains two clusters of basic residues, 44RKNR47 and55KKWVR59. The first is a BBXB motif common in heparin-binding proteins, and the second is located in the loop directly preceding the C-terminal helix. We have mutated these residues to alanine, both as point mutations as well as triple mutations of the 40s and 50s clusters. Using a binding assay to heparin beads with radiolabeled proteins, the44AANA47 mutant demonstrated an 80% reduction in its capacity to bind heparin, whereas the55AAWVA59 mutant retained full binding capacity. Mutation of the 44RKNR47 site reduced the selectivity of RANTES binding to different GAGs. The mutants were tested for their integrity by receptor binding assays on CCR1 and CCR5 as well as their ability to induce chemotaxis in vitro. In all assays the single point mutations and the triple 50s cluster mutation caused no significant difference in activity compared with the wild type sequence. However, the triple 40s mutant showed a 80-fold reduction in affinity for CCR1, despite normal binding to CCR5. It was only able to induce monocyte chemotaxis at micromolar concentrations. The triple 40s mutant was also able to inhibit HIV-1 infectivity, but consistent with its abrogated GAG binding capacity, it no longer induced enhanced infectivity at high concentrations.</description><identifier>ISSN: 0021-9258</identifier><identifier>EISSN: 1083-351X</identifier><identifier>DOI: 10.1074/jbc.M010867200</identifier><identifier>PMID: 11116158</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Animals ; Binding Sites - genetics ; Chemokine CCL5 - chemistry ; Chemokine CCL5 - genetics ; Chemokine CCL5 - metabolism ; CHO Cells ; Cricetinae ; Heparin - metabolism ; Mutation ; Protein Binding - genetics ; Receptors, CCR5 ; Receptors, Chemokine - chemistry ; Receptors, Chemokine - genetics ; Receptors, Chemokine - metabolism ; Transfection</subject><ispartof>The Journal of biological chemistry, 2001-04, Vol.276 (14), p.10620-10626</ispartof><rights>2001 © 2001 ASBMB. Currently published by Elsevier Inc; originally published by American Society for Biochemistry and Molecular Biology.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c475t-a6cdd54825bf301cdd4a6d4970127049a56af056c11d84300ec9e0b2ff79d9ab3</citedby><cites>FETCH-LOGICAL-c475t-a6cdd54825bf301cdd4a6d4970127049a56af056c11d84300ec9e0b2ff79d9ab3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11116158$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Proudfoot, Amanda E.I.</creatorcontrib><creatorcontrib>Fritchley, Sarah</creatorcontrib><creatorcontrib>Borlat, Frédéric</creatorcontrib><creatorcontrib>Shaw, Jeffrey P.</creatorcontrib><creatorcontrib>Vilbois, Francis</creatorcontrib><creatorcontrib>Zwahlen, Catherine</creatorcontrib><creatorcontrib>Trkola, Alexandra</creatorcontrib><creatorcontrib>Marchant, David</creatorcontrib><creatorcontrib>Clapham, Paul R.</creatorcontrib><creatorcontrib>Wells, Timothy N.C.</creatorcontrib><title>The BBXB Motif of RANTES Is the Principal Site for Heparin Binding and Controls Receptor Selectivity</title><title>The Journal of biological chemistry</title><addtitle>J Biol Chem</addtitle><description>The chemokine RANTES (regulated on activation normal T cell expressed and secreted; CCL5) binds selectively to glycosaminoglycans (GAGs) such as heparin, chondroitin sulfate, and dermatan sulfate. The primary sequence of RANTES contains two clusters of basic residues, 44RKNR47 and55KKWVR59. The first is a BBXB motif common in heparin-binding proteins, and the second is located in the loop directly preceding the C-terminal helix. We have mutated these residues to alanine, both as point mutations as well as triple mutations of the 40s and 50s clusters. Using a binding assay to heparin beads with radiolabeled proteins, the44AANA47 mutant demonstrated an 80% reduction in its capacity to bind heparin, whereas the55AAWVA59 mutant retained full binding capacity. Mutation of the 44RKNR47 site reduced the selectivity of RANTES binding to different GAGs. The mutants were tested for their integrity by receptor binding assays on CCR1 and CCR5 as well as their ability to induce chemotaxis in vitro. In all assays the single point mutations and the triple 50s cluster mutation caused no significant difference in activity compared with the wild type sequence. However, the triple 40s mutant showed a 80-fold reduction in affinity for CCR1, despite normal binding to CCR5. It was only able to induce monocyte chemotaxis at micromolar concentrations. The triple 40s mutant was also able to inhibit HIV-1 infectivity, but consistent with its abrogated GAG binding capacity, it no longer induced enhanced infectivity at high concentrations.</description><subject>Animals</subject><subject>Binding Sites - genetics</subject><subject>Chemokine CCL5 - chemistry</subject><subject>Chemokine CCL5 - genetics</subject><subject>Chemokine CCL5 - metabolism</subject><subject>CHO Cells</subject><subject>Cricetinae</subject><subject>Heparin - metabolism</subject><subject>Mutation</subject><subject>Protein Binding - genetics</subject><subject>Receptors, CCR5</subject><subject>Receptors, Chemokine - chemistry</subject><subject>Receptors, Chemokine - genetics</subject><subject>Receptors, Chemokine - metabolism</subject><subject>Transfection</subject><issn>0021-9258</issn><issn>1083-351X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kE1PGzEQhq2KqqTAtcfKB8Rt07H3-0iiUJCgRSRI3CyvPSZGm_ViOyD-fR0lEqfOxR77mVejh5AfDKYM6uLXS6emd8CgqWoO8IVM0jXP8pI9HZEJAGdZy8vmmHwP4QVSFS37Ro5ZqoqVzYTo1RrpbPY0o3cuWkOdoQ-Xf1aLJb0JNKa_e28HZUfZ06WNSI3z9BpHmV7pzA7aDs9UDprO3RC96wN9QIVjTNQSe1TRvtn4cUq-GtkHPDucJ-TxarGaX2e3f3_fzC9vM1XUZcxkpbQui4aXncmBpaaQlS7aGhiv0-ayrKSBslKM6abIAVC1CB03pm51K7v8hFzsc0fvXrcYotjYoLDv5YBuG0S9SwLeJHC6B5V3IXg0YvR2I_2HYCB2XkXyKj69poGfh-Rtt0H9iR9EJuB8D6zt8_rdehSddWqNG8HrSrAipVZ8l9PsMUwa3ix6EZTFQaFOIyoK7ez_VvgHUbWQuw</recordid><startdate>20010406</startdate><enddate>20010406</enddate><creator>Proudfoot, Amanda E.I.</creator><creator>Fritchley, Sarah</creator><creator>Borlat, Frédéric</creator><creator>Shaw, Jeffrey P.</creator><creator>Vilbois, Francis</creator><creator>Zwahlen, Catherine</creator><creator>Trkola, Alexandra</creator><creator>Marchant, David</creator><creator>Clapham, Paul R.</creator><creator>Wells, Timothy N.C.</creator><general>Elsevier Inc</general><general>American Society for Biochemistry and Molecular Biology</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20010406</creationdate><title>The BBXB Motif of RANTES Is the Principal Site for Heparin Binding and Controls Receptor Selectivity</title><author>Proudfoot, Amanda E.I. ; Fritchley, Sarah ; Borlat, Frédéric ; Shaw, Jeffrey P. ; Vilbois, Francis ; Zwahlen, Catherine ; Trkola, Alexandra ; Marchant, David ; Clapham, Paul R. ; Wells, Timothy N.C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c475t-a6cdd54825bf301cdd4a6d4970127049a56af056c11d84300ec9e0b2ff79d9ab3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Animals</topic><topic>Binding Sites - genetics</topic><topic>Chemokine CCL5 - chemistry</topic><topic>Chemokine CCL5 - genetics</topic><topic>Chemokine CCL5 - metabolism</topic><topic>CHO Cells</topic><topic>Cricetinae</topic><topic>Heparin - metabolism</topic><topic>Mutation</topic><topic>Protein Binding - genetics</topic><topic>Receptors, CCR5</topic><topic>Receptors, Chemokine - chemistry</topic><topic>Receptors, Chemokine - genetics</topic><topic>Receptors, Chemokine - metabolism</topic><topic>Transfection</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Proudfoot, Amanda E.I.</creatorcontrib><creatorcontrib>Fritchley, Sarah</creatorcontrib><creatorcontrib>Borlat, Frédéric</creatorcontrib><creatorcontrib>Shaw, Jeffrey P.</creatorcontrib><creatorcontrib>Vilbois, Francis</creatorcontrib><creatorcontrib>Zwahlen, Catherine</creatorcontrib><creatorcontrib>Trkola, Alexandra</creatorcontrib><creatorcontrib>Marchant, David</creatorcontrib><creatorcontrib>Clapham, Paul R.</creatorcontrib><creatorcontrib>Wells, Timothy N.C.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of biological chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Proudfoot, Amanda E.I.</au><au>Fritchley, Sarah</au><au>Borlat, Frédéric</au><au>Shaw, Jeffrey P.</au><au>Vilbois, Francis</au><au>Zwahlen, Catherine</au><au>Trkola, Alexandra</au><au>Marchant, David</au><au>Clapham, Paul R.</au><au>Wells, Timothy N.C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The BBXB Motif of RANTES Is the Principal Site for Heparin Binding and Controls Receptor Selectivity</atitle><jtitle>The Journal of biological chemistry</jtitle><addtitle>J Biol Chem</addtitle><date>2001-04-06</date><risdate>2001</risdate><volume>276</volume><issue>14</issue><spage>10620</spage><epage>10626</epage><pages>10620-10626</pages><issn>0021-9258</issn><eissn>1083-351X</eissn><abstract>The chemokine RANTES (regulated on activation normal T cell expressed and secreted; CCL5) binds selectively to glycosaminoglycans (GAGs) such as heparin, chondroitin sulfate, and dermatan sulfate. The primary sequence of RANTES contains two clusters of basic residues, 44RKNR47 and55KKWVR59. The first is a BBXB motif common in heparin-binding proteins, and the second is located in the loop directly preceding the C-terminal helix. We have mutated these residues to alanine, both as point mutations as well as triple mutations of the 40s and 50s clusters. Using a binding assay to heparin beads with radiolabeled proteins, the44AANA47 mutant demonstrated an 80% reduction in its capacity to bind heparin, whereas the55AAWVA59 mutant retained full binding capacity. Mutation of the 44RKNR47 site reduced the selectivity of RANTES binding to different GAGs. The mutants were tested for their integrity by receptor binding assays on CCR1 and CCR5 as well as their ability to induce chemotaxis in vitro. In all assays the single point mutations and the triple 50s cluster mutation caused no significant difference in activity compared with the wild type sequence. However, the triple 40s mutant showed a 80-fold reduction in affinity for CCR1, despite normal binding to CCR5. It was only able to induce monocyte chemotaxis at micromolar concentrations. The triple 40s mutant was also able to inhibit HIV-1 infectivity, but consistent with its abrogated GAG binding capacity, it no longer induced enhanced infectivity at high concentrations.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>11116158</pmid><doi>10.1074/jbc.M010867200</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0021-9258
ispartof The Journal of biological chemistry, 2001-04, Vol.276 (14), p.10620-10626
issn 0021-9258
1083-351X
language eng
recordid cdi_proquest_miscellaneous_77012028
source MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
subjects Animals
Binding Sites - genetics
Chemokine CCL5 - chemistry
Chemokine CCL5 - genetics
Chemokine CCL5 - metabolism
CHO Cells
Cricetinae
Heparin - metabolism
Mutation
Protein Binding - genetics
Receptors, CCR5
Receptors, Chemokine - chemistry
Receptors, Chemokine - genetics
Receptors, Chemokine - metabolism
Transfection
title The BBXB Motif of RANTES Is the Principal Site for Heparin Binding and Controls Receptor Selectivity
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T10%3A07%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20BBXB%20Motif%20of%20RANTES%20Is%20the%20Principal%20Site%20for%20Heparin%20Binding%20and%20Controls%20Receptor%20Selectivity&rft.jtitle=The%20Journal%20of%20biological%20chemistry&rft.au=Proudfoot,%20Amanda%20E.I.&rft.date=2001-04-06&rft.volume=276&rft.issue=14&rft.spage=10620&rft.epage=10626&rft.pages=10620-10626&rft.issn=0021-9258&rft.eissn=1083-351X&rft_id=info:doi/10.1074/jbc.M010867200&rft_dat=%3Cproquest_cross%3E77012028%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=77012028&rft_id=info:pmid/11116158&rft_els_id=S0021925819344904&rfr_iscdi=true